"The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.
There has been no experience with acute overdose of Panretin® (alitretinoin) gel in humans. Systemic toxicity following acute overdosage with topical application of Panretin® (alitretinoin) gel is unlikely because of limited systemic plasma levels observed with normal therapeutic doses. There is no specific antidote for overdosage.
Panretin® (alitretinoin) gel is contraindicated in patients with a known hypersensitivity to retinoids or to any of the ingredients of the product.
Last reviewed on RxList: 11/17/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Panretin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.